• Explore /
  • Poster
  • / Analysis of circulating tumor DNA in the phase 2 BTCRC LUN 16-081 trial of consolidation nivolumab with or without ipilimumab after chemoradiation in stage III non–small cell lung cancer.

Analysis of circulating tumor DNA in the phase 2 BTCRC LUN 16-081 trial of consolidation nivolumab with or without ipilimumab after chemoradiation in stage III non–small cell lung cancer.

Abstract Poster

Authors

null

Soyeong Jun

Stanford Cancer Institute, Stanford University, Stanford, CA

Soyeong Jun , Nikhil Shukla , Greg Andrew Durm , Angela B. Hui , Sha Cao , Christian Kunder , Ash A. Alizadeh , Nasser H. Hanna , Maximilian Diehn

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Biologic Correlates

Clinical Trial Registration Number

NCT03285321

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 8534)

DOI

10.1200/JCO.2022.40.16_suppl.8534

Abstract #

8534

Poster Bd #

161

Abstract Disclosures

Similar Posters

First Author: Cynthia Wei

First Author: Greg Andrew Durm

First Author: Greg Andrew Durm

First Author: Maria Constantinou